Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Derde generatie anti-CD19 CAR T-cellen voor gerecidiveerde/refractaire CLL
jan 2025 | Leukemie, Lymfoom